CA Patent

CA2914791A1 — Dpp-4 inhibitors for treating diabetes and its complications

Assigned to Boehringer Ingelheim International GmbH · Expires 2014-12-18 · 11y expired

What this patent protects

The present invention relates to the use of a certain DPP-4 inhibitor along with angioplasty or stenting, and/or to its use for treating and/or preventing restenosis from angioplasty or stenting.

USPTO Abstract

The present invention relates to the use of a certain DPP-4 inhibitor along with angioplasty or stenting, and/or to its use for treating and/or preventing restenosis from angioplasty or stenting.

Drugs covered by this patent

Patent Metadata

Patent number
CA2914791A1
Jurisdiction
CA
Classification
—
Expires
2014-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.